We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$2.05B 30.56%
19,991,024
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$279M 4.16%
23,993,023
+2,597,527
+12% +$30M
CNC icon
3
Centene
CNC
$32.8B
$200M 2.98%
2,652,189
+2,067
+0.1% +$152K
MRUS
4
DELISTED
Merus
MRUS
$170M 2.54%
3,408,539
+659,138
+24% +$34.4M
OSCR icon
5
Oscar Health
OSCR
$8.77B
$167M 2.49%
7,851,675
+891,888
+13% +$16.1M
SPRY icon
6
ARS Pharmaceuticals
SPRY
$695M
$161M 2.4%
11,077,927
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.2B
$152M 2.27%
1,316,590
+625,586
+91% +$85.8M
LRMR icon
8
Larimar Therapeutics
LRMR
$384M
$139M 2.08%
21,231,974
– –
WAY
9
Waystar Holding Corp
WAY
$4.27B
$138M 2.06%
4,952,004
– –
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$132M 1.97%
2,912,692
-177,381
-6% -$7.72M
ALHC icon
11
Alignment Healthcare
ALHC
$4.26B
$128M 1.92%
10,854,985
-46,500
-0.4% -$440K
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$124M 1.85%
6,229,634
-2,897,671
-32% -$53.7M
AHCO icon
13
AdaptHealth
AHCO
$1.49B
$109M 1.63%
9,711,410
-3,546,530
-27% -$37.7M
BKD icon
14
Brookdale Senior Living
BKD
$3.58B
$106M 1.58%
15,612,264
– –
KURA icon
15
Kura Oncology
KURA
$964M
$106M 1.58%
5,411,571
– –
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.47B
$82.2M 1.23%
2,594,000
+496,887
+24% +$18.8M
ACH
17
Accendra Health
ACH
$266M
$77.1M 1.15%
4,911,979
-1,459,461
-23% -$22.1M
BAX icon
18
Baxter International
BAX
$11.7B
$73M 1.09%
1,923,100
+345,453
+22% +$12.7M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.36B
$61.8M 0.92%
8,135,804
– –
SGRY icon
20
Surgery Partners
SGRY
$2.09B
$57.4M 0.86%
1,780,287
-2,927,000
-62% -$86.4M
CVS icon
21
CVS Health
CVS
$137B
$55M 0.82%
874,800
-100,200
-10% -$5.85M
CGEM icon
22
Cullinan Oncology
CGEM
$1.09B
$54.9M 0.82%
3,280,000
-237
-0% -$4.2K
BIO icon
23
Bio-Rad Laboratories Class A
BIO
$8.15B
$50.7M 0.76%
151,575
-139
-0.1% -$44.1K
IRON icon
24
Disc Medicine
IRON
$2.91B
$50.3M 0.75%
1,023,265
– –
INDV icon
25
Indivior Pharmaceuticals
INDV
$4.79B
$49.7M 0.74%
+5,092,642
New +$59.6M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.